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ABSTRACT

ABSTRACT
INTRODUCTION:
The risk of cardiovascular diseases in people living with HIV is
greater than in normal individuals
OBJECTIVES:
1. To Assess the cardiovascular risks in people living with HIV with
HAART using standard cardiovascular risk scores.
2. To compare the pattern of cardiovascular disease risk associated with
HIV seropositive patients with HAART.
METHODOLOGY:
Patients diagnosed with HIV with HAART with one or other
cardiovascular diseases will be enrolled. The data related to various
cardiovascular diseases, the duration of cardiovascular disease with onset of
HIV infection with HAART. The enrolled patients will be evaluated by using
various validated cardiovascular risk scores like the Framingham risk score,
American College of Cardiology/American heart association (ACC/AHA) risk
score, the Second manifestations of arterial disease (SMART) risk scores. The
outcome of the result scores will be compared between the various scores and
risk will be categorized. The pattern of cardiovascular risk with its incidence
will be reported.
RESULTS:
When the results of the Framingham score was compared with that of the
AHA score the kappa coefficient value obtained was 0.282 which shows a fair
agreement (0.21 – 0.40) between these two scores. In a similar way, the results
of SMART score was compared with that of AHA score, the kappa coefficient
value was 0.597 which shows a moderate agreement (0.41 – 0.60) between the
scores. And when the results of the Framingham score were compared with
SMART score the kappa coefficient value was 0.250 which shows a fair
agreement (0.21 – 0.40) between the scores.
CONCLUSION:

ACC/AHA score is the most commonly used score for cv risk
scoring India, and when it was compared with Framingham and
SMART score showed fair to moderate agreement concluding that
these scores can also be used in addition to AHA score for calculating
cv risk scores in India.
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1. INTRODUCTION:
Human immunodeficiency virus (HIV)/ Acquired immunodeficiency
syndrome (AIDS) is a chronic illness. Around the world, approximately 36.9 million
people are currently living with HIV/AIDS, of these around 1.8 million children
(<15 years) are infected by HIV positive mother during pregnancy, childbirth or
breastfeeding. In 2004 approximately 1.9 million people living with HIV were
accessing treatment through highly active antiretroviral therapy (HAART) which is
a combination of two nucleoside reverse transcriptase inhibitors (NRTI), a protease
inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI), with an
increase of 1.4 million people in 2010 and 8 million in 2016 and 21.7 million in
2017. AIDS-related deaths have been lowered by more than 51% since 2004. In
2017, 940 000 people have died from AIDS compared to 1.4 million in 2010 and 1.9
million in 2004 respectively.
People living with HIV (PLW-HIV) are living long enough to experience nonAIDS related illness. This includes chronic obstructive pulmonary disorder,
diabetes, kidney diseases, hypertension, cardiovascular diseases(CVD) and cancer.
CVD a commonly used term for diseases of the heart and blood vessels is the number
one cause of death worldwide. It is projected that annual global cardiovascular
deaths will increase from 16.7 million in 2002 to 23.9 million by 2030. Furthermore,
the estimated risk of cardiovascular diseases in PLW-HIV is 61% more.
The advent of HAART has been associated with a profound reduction in
morbidity and mortality from HIV/AIDS. However, several reports have
documented the increased prevalence of CVD risk factors (such as obesity, elevated
blood pressure, elevated blood sugar, hypertriglyceridemia, and low high-density
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lipoprotein cholesterol (HDL-c)) in both HAART-treated and HAART-naïve
patients.
The occurrence of non-AIDS-related morbidities might be higher in PLW-HIV
than in the general population for three main reasons. First, the HIV-positive
population in high-income settings has a high level of traditional risk factors for nonAIDS morbidities, such as smoking and hepatitis, co-infection. Second, available
evidence suggests that the persistent immunodeficiency, immune dysregulation,
immune activation, and inflammation associated with HIV infection, including
patients on ART, might increase the risk of some of these morbidities. Third,
antiretroviral-related adverse events such as dyslipidemia and diabetes might also
play a part.
Immune dysfunction and persistent inflammation features of HIV infection
have a possible role in the pathogenesis of CVD risk in addition to traditional risk
factors such as cigarette smoking, elevated blood pressure, and total cholesterol.
WHO recommends that the assessment and management of CVD should be
provided for all PLW-HIV. There are various risk estimators to calculate the risk of
developing cardiovascular diseases in people such as Framingham risk score(FRS),
American college of cardiology/American heart association (ACC/AHA) risk
estimator, Second manifestations of arterial disease (SMART) risk score(1).
American College of Cardiology/American Heart Association (ACC/AHA) is
the most commonly used risk score for estimating the cardiovascular risk in India.
However, the best score for estimating the risk of cardiovascular diseases is
unknown. There are no studies performed in PLW-HIV to estimate cardiovascular
risk in India. Therefore, this study was to assess the CVD risk scores in PLW-HIV
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who are on HAART and to assess for the possible risk related to CVD using three
different CVD risk scores.
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2. REVIEW OF LITERATURE:
The aim of this study was to compare the predictions of Framingham
cardiovascular (CV) risk score (FRS) and the American College of
Cardiology/American Heart Association (ACC/AHA) risk score in an HIV
outpatient clinic in the city of Vitoria, Espirito Santo, Brazil. In a cross-sectional
study 341, HIV infected patients over 40 years old consecutively recruited were
interviewed. Cohen’s kappa coefficient was used to assess agreement between the
two algorithms. 61.3% were stratified as low risk by Framingham score, compared
with 54% by ACC/AHA score (Spearman correlation 0.845; p < 0.000). Only 26.1%
were classified as cardiovascular high risk by Framingham compared to 46% by
ACC/AHA score (Kappa = 0.745; p < 0.039). Only one out of eight patients had a
cardiovascular high risk by Framingham at the time of a myocardial infarction event
registered up to five years before the study period. Both cardiovascular risk scores
but especially Framingham underestimated high-risk patients in this HIV-infected
population(1).
This study used a mathematical model to project cumulative CVD incidence.
They simulated a male and female cohort for each of 3 populations: US general
population; HIV-uninfected, at high risk for HIV; and PLWH and incorporated the
higher smoking prevalence and increased CVD risk due to smoking into the HIVinfected and HIV-uninfected, at high risk for HIV populations. They incorporated
HIV-attributable CVD risk, independent of smoking. For men, life expectancy
ranged from 70.2 to 77.5 years and for women from 67.0 to 81.1 years (PLWH, US
general population). Without antiretroviral therapy, lifetime CVD risk for HIVinfected males and females was 12.9% and 9.0%. For males, by age 60, cumulative
CVD incidence was estimated at 20.5% in PLWH in care, 14.6% in HIV-uninfected
high-risk persons, and 12.8% in the US general population. For females, cumulative
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CVD incidence was projected to be 13.8% in PLWH in care, 9.7% for high-risk
HIV-uninfected persons, and 9.4% in the US general population. Lifetime CVD risk
was 64.8% for HIV-infected males compared to 54.8% for males in the US general
population, but similar among females (2).
This was a cross-sectional study of HIV-positive patients attending the Lagos
University Teaching Hospital, Nigeria. Anthropometric and blood pressure
measurements were performed; fasting lipid profile, plasma glucose, homocysteine,
and hsCRP were determined, as well as prevalences and risk assessments. Statistical
tests were used to compare the groups and p-value <0.05 was considered to be
significant. 283 subjects were recruited for this study (100 HIV-positive treatmentnaive, 100 HIV-positive treated and 83 HIV negative controls). Compared to the
controls, mean (sd) values were significantly higher among HIV-treated subjects:
waist circumference=88.7 (10.4), p=0.035; systolic bp= 124.9 (20.7), p=0.014;
glucose= 5.54 (1.7), p=0.015; triglyceride= 2.0 (1.2), p<0.001; homocysteine= 10.9
(8.9-16.2), p=0.0003; while hsCRP= 2.9 (1.4-11.6), p=0.002 and HDL-C=0.9 (0.4),
p=<0.0001 were higher among the HIV-naive subjects. Likewise, higher prevalence
of the risk factors was noted among the HIV-treated subjects except low HDL-C
(p<0.001) and hsCRP (p=0.03) which were higher in the HIV naive group. Risk
assessment using ratios showed a high risk for CVD, especially in the HIV-naive
group. The median range for Framingham risk assessment was 1.0 - 7.5%(3).
This study was a systematic review and meta-analysis of studies from the peerreviewed literature. Eligible studies were observational and randomized controlled
trials, reporting CVD, defined as myocardial infarction (MI), ischemic heart disease,
cardiovascular and cerebrovascular events or coronary heart disease among HIVpositive adults. Pooled relative risks were calculated for various groupings,
including different classes of antiretroviral therapy (ART). The relative risk of CVD
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was 1.61 [95% confidence interval (CI) 1.43–1.81] among PLWHIV without ART
compared with HIV-uninfected people. The relative risk of CVD was 2.00 (95% CI
1.70–2.37) among PLHIV on ART compared with HIV-uninfected people and 1.52
(95% CI 1.35–1.70) compared with treatment-naïve PLWHIV. We estimate the
relative risk of CVD associated with protease inhibitor (PI), nucleoside reverse
transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-based ART
to be 1.11 (95% CI 1.05–1.17), 1.05 (95% CI 1.01–1.10) and 1.04 (95% CI 0.99–
1.09) per year of exposure, respectively. Not all ART was associated with increased
risk; specifically, lopinavir/ritonavir and abacavir were associated with the greater
risk and the relative risk of MI for PI-based versus non-PI-based ART was 1.41 (95%
CI 1.20–1.65) (4).
This was a cross-sectional study. Adults with HIV infection were studied.
Demographic, clinical and anthropometric data, serum glucose and lipids were
obtained. Cardiovascular risk was calculated through the Framingham risk score
(FRS) and CACS. Categorical variables were compared by Chi-square or Fisher’s
exact test, and continuous variables were analyzed by Student t test or MannWhitney test. An analysis of concordance between FRS and CACS was performed
using the kappa statistic. Forty patients aged 45.9 } 8.1 years, were studied. Age of
risk for CAD were found in 30.0%, hypertension in 55.0%, diabetes in 10.0%,
smoking in 35.0%, dyslipidemia in 67.5% and family history of CAD in 57.5%.
Altered levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, and
triglycerides were found in 30.0%, 25.0%, and 82.5%, respectively. HDLcholesterol and triglycerides were altered more frequently among protease inhibitors
users. The FRS classified the risk as low for 72.5%, moderate for 25.0%, and high
for 2.5%. CACS > 0 was found in 32.5% of the patients, in 67.5% the score was low,
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in 17.5% moderate, and in 15.0% high. Concordance between FRS and CACS
showed a kappa = 0.435(5).
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3. OBJECTIVES:
1) To Assess the cardiovascular risks in people living with HIV with HAART
using standard cardiovascular risk scores.
2) To compare the pattern of cardiovascular disease risk associated with HIV
seropositive patients with HAART.
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4. METHODOLOGY:
Study Site:
Department of Medicine, Kasturba Hospital, Manipal.

Study duration:
This study was conducted for a period of 6 months. From November 2018 to April
2019.
Ethical Approval:
The protocol for this study was approved by the institutional Ethical Committee of
Kasturba Hospital, Manipal.
Study Criteria:
a) Inclusion criteria:
1) Patients who are above 18 years of age and diagnosed with HIV
and who are on HAART with one or other cardiovascular disease.
b) Exclusion criteria:
1. Patients with long-term malignancy, renal failure patients and
pregnant women will be excluded.
2. Patients who are above 18 years of age and diagnosed with HIV
and who are not on HAART with one or other cardiovascular
disease will be excluded.
Sample size: 141 patients.
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Statistical methods: SPSS 20.
Cohen’s kappa coefficient is used to assess the agreement between the three
cardiovascular risk assessment scores.
Study procedure:
Patients diagnosed with HIV with HAART with one or other cardiovascular
diseases will be enrolled by referring with the medical records between January 2016
to December 2017 from medical records department (MRD) with institutional
ethical approval clearance. The data related to various cardiovascular diseases such
as Myocardial infarction, angina pectoris, congestive cardiac failure, arrhythmias
and other cardiovascular blood vessel disorders will be documented, (like HDL, total
cholesterol, SBP, DBP, hypertensive medication, BMI, smoking and alcoholic
habits) the duration of cardiovascular disease with onset of HIV infection with
HAART. The enrolled patients based on inclusion and exclusion criteria will be
evaluated by using various validated cardiovascular risk scores like the Framingham
risk score, American College of Cardiology/American heart association
(ACC/AHA) risk score, the Second manifestations of arterial disease (SMART) risk
scores. The outcome of the result scores will be compared between the various scores
and risk will be categorized into low, moderate and severe risk. The data collected
will be analyzed using SPSS software, Cohen’s kappa coefficient will be used to
determine the agreement between the scores.
Cohen’s kappa coefficient is the statistical method used to assess the agreement
between two different variables, this method will determine the degree of agreement
between the variables when compared with each other. Based on the kappa
coefficient value the result is categorized into various categories such as poor
agreement, slight agreement, fair agreement, moderate agreement, substantial
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agreement, and almost perfect agreement. As the coefficient value increases the
degree of agreement between the scores also increases.

Outcome measures:
Cardiovascular risk outcomes using various cardiovascular risk scores will be
evaluated and reported with its pattern and incidence.
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Patients diagnosed with HIV with HAART
are enrolled from the MRD.

The data related to various
cardiovascular diseases will be
documented.

The enrolled patients based on
inclusion and exclusion criteria will be
evaluated by using various
cardiovascular risk scores.

The outcome of the result scores will
be compared between the various
scores and risk will be categorized.

The scores obtained by the three
scores will be compared and
assessed by cohen's kappa
coefficient.
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RESULTS & DISCUSSION
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RESULTS
& DISCUSSION
Table-1
: Demographic
Details Of HIV Patients For Cardiovascular Risk Scores

ACC/AHA FRAMINGHAM
SCORE
SCORE
N=141(%) N=133(%)

SMART
SCORE
N=90(%)

Male

108(76.6)

102(76.6)

75(83.3)

Female

33(23.4)

31(23.3)

15(16.7)

20-39

53(37.6)

45(33.8)

2(2.2)

40-59

84(59.6)

84(63.1)

84(93.3)

>60

4(2.8)

4(3.0)

4(4.5)

<19.9

57(40.4)

54(40.6)

39(43.3)

20-24.9

31(22.0)

29(21.8)

20(22.2)

>25

10(7.1)

10(7.5)

8(8.9)

Not Able to Stand 43(30.5)

40(30.0)

23(25.6)

Vegetarian

2(1.4)

1(0.7)

Mixed Diet

139(98.6)

132(99.3)

90(100.0)

Employed

114(80.9)

107(80.5)

79(87.8)

Unemployed

27(19.1)

26(19.5)

11(12.2)

Never

123(87.2)

117(87.9)

78(86.6)

Social

3(2.1)

2(1.5)

2(2.2)

Habitual

8(5.7)

8(6.0)

5(5.5)

Reformed

7(5.0)

6(4.5)

5(5.5)

Past Smoker

4(2.8)

4(3)

3(3.3)

Never

129(91.5)

122(91.7)

83(92.2)

Current Smoker

8(5.7)

7(5.3)

4(4.5)

<120

59(41.8)

57(42.9)

35(38.9)

120-150

78(55.3)

72(54.1)

51(56.6)

CHARACTERISTICS

Gender

Age In Years.

BMI

Diet

Employment Status

Alcoholic Habits

Smoking Habits

SBP (Systolic Blood
Pressure)

--
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DBP(Diastolic Blood
Pressure)
Total Cholesterol

HDL

Marital Status

CD4 Cell Count

Hypertensive
Medication

<80

63(44.7)

60(45.1)

39(43.3)

80-100

78(55.3)

73(54.9)

51(56.7)

50-100

9(6.4)

8(6.0)

5(5.5)

100-150

67(47.5)

63(47.4)

39(43.3)

150-200

61(43.3)

59(44.4)

44(48.9)

>200

4(2.8)

3(3.3)

2(2.2)

0-30

44(31.2)

41(30.8)

26(28.9)

30-60

78(55.3)

73(54.9)

49(54.4)

60-90

19(13.5)

19(14.3)

15(16.7)

Married

114(80.9)

111(83.5)

82(91.1)

Unmarried

25(17.7)

20(15.0)

6(6.7)

Divorced

2(1.4)

2(1.5)

2(2.2)

<=150

90(63.8)

85(63.9)

58(64.4)

150-300

22(15.6)

20(15.0)

13(14.4)

300-500

19(13.5)

19(14.3)

11(12.3)

>500

10(7.1)

9(6.8)

8(8.9)

Yes

7(5.0)

7(5.3)

7(7.8)

No

134(95.0)

126(94.7)

83(92.2)

As per Framingham score, the minimum age for calculation of cardiovascular risk is 30 years hence, the patients
below 30 years of age were not able to evaluate.
As per SMART risk score, the minimum age for calculation of cardiovascular risk with that score is 40 years hence,
the patients below 40 years of age were not able to evaluate.
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Out of the 141 patients enrolled, according to ACC/AHA Score majority of them
108 (76.6%) were male and 33 (23.4%) were female. A majority, 84 (59.6%) were
in the age group of 40-59 years, followed by 53 (37.6%) patients in the age group of
20-39 years, and least number 4 (2.8%) belong to the age group of >60 years. BMI
values showed that 57 (40.4%) falls under the category <19.9, 43 (30.5%) were not
able to stand, 31 (22%) are patients between a range of 20-24.9 and 10 (7.1%) falls
under >25. Majority patients 139 (98.6%) had mixed diet and 2 (0.4%) had
vegetarian diet. Most of the patients were employed 114 (80.9%) and very few 27
(19.1%) were unemployed. Majority of the patients 123 (87.2%) never had alcohol
followed by 8 (5.7%) who were habitual alcohol drinkers followed by 7 (5%) who
were reformed drinkers, followed by 3 (2.1%) who were social drinkers. Majority of
the patients 129 (91.5%) have never smoked, 8 (5.7%) are current smokers and 4
(2.8%) were past smokers. Majority of the patients 78 (55.3%) had systolic blood
pressure in the range of 120-150, 59 (41.8%) had <120, 4 (2.8%) had >150. Majority
of the patients 78 (55.3%) had diastolic blood pressure in the range of 80-100,
followed by 63 (44.7%) who had <80. Majority of the patients 67 (47.5%) had total
cholesterol in the range of 100-150, followed by 61 (43.3%) who were in the range
of 150-200 and followed by 4 (2.8%) had >200. Most of the patients 78 (55.3%) had
HDL in the range of 30-60, followed by 44 (31.2%) who were in the range of 0-30,
followed by 19 (13.5%) who had 60-90. Most of the patients 114 (80.9%) were
married followed by 25 (17.7%) were single and 2 (1.4%) were divorced. Majority
of the patients 90 (63.8%) had a CD4 cell count of <=150, followed by 22 (15.6%)
were in the range of 150-300 cells, followed by 19 (13.5%) were in the range of 300500 cells followed by 10 (7.1%) had more than 500 cells. Majority of the patients
134 (95%) were not on any hypertensive medication, followed by 7 (5%) were on
medication.
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Out of the 133 patients enrolled, according to Framingham Score majority of
them 102 (76.6%) were male and 31 (23.3%) were female. A majority, 84 (63.1%)
were in the age group of 40-59 years, followed by 45 (33.8%) patients in the age
group of 20-39 years, and least number 4 (3%) belong to the age group of >60 years.
BMI values showed that 54 (40.6%) falls under the category <19.9, 40 (30%) were
not able to stand, 29 (21.8%) are patients between a range of 20-24.9 and 10 (7.5%)
falls under >25. Majority patients 132 (99.3%) had mixed diet and 1 (0.7%) had
vegetarian diet. Majority patients were employed 107 (80.4%) and very few 26
(19.5%) were unemployed. Majority of the patients 117 (87.9%) never had alcohol
followed by 8 (6%) who were habitual alcohol drinkers followed by 6 (4.5%) who
were reformed drinkers, followed by 2 (1.5%) who were social drinkers. Majority of
the patients 122 (91.7%) have never smoked, 7 (5.3%) are a current smoker and 4
(3%) were past smokers. Majority of the patients 72 (54.1%) had systolic blood
pressure in the range of 120-150, 57 (42.9%) had <120, 4 (3%) had >150. Majority
of the patients 73 (54.9%) had diastolic blood pressure in the range of 80-100,
followed by 60 (45.1%) who had <80. Majority of the patients 63 (47.4%) had total
cholesterol in the range of 100-150, followed by 59 (44.4%) who were in the range
of 150-200 and followed by 3 (3.3%) had >200. Majority of the patients 73 (54.9%)
had HDL in the range of 30-60, followed by 41 (30.8%) who were in the range of 030, followed by 19 (14.3%) who had 60-90. Majority of the patients 111 (83.5%)
were married followed by 20 (15%) were single and 2 (1.5%) were divorced.
Majority of the patients 85 (63.9%) had a CD4 cell count of <=150, followed by 20
(15%) were in the range of 150-300 cells, followed by 19 (14.3%) were in the range
of 300-500 cells followed by 9 (6.8%) had more than 500 cells. Majority of the
patients 126 (94.7%) were not on any hypertensive medication, followed by 7 (5.3%)
were on medication.
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Out of the 90 patients enrolled, according to SMART Score majority of
them 75 (83.3%) were male and 15 (16.7%) were female. A majority, 84 (93.3%)
were in the age group of 40-59 years, and least number 4 (4.5%) belong to the age
group of >60 years. BMI values showed that 39 (43.3%) falls under the category
<19.9, 23 (25.6%) were not able to stand, 20 (22.2%) are patients between a range
of 20-24.9 and 8 (8.9%) falls under >25. All the patients 90 (100%) had a mixed
diet. Majority patients were employed 79 (87.8%) and very few 11 (12.2%) were
unemployed. Majority of the patients 78 (86.6%) never had alcohol followed by 5
(5.5%) who were habitual and reformed drinkers, followed by 2 (2.2%) who were
social drinkers. Majority of the patients 83 (92.2%) have never smoked, 4 (4.5%)
are a current smoker and 3 (3.3%) were past smokers. Majority of the patients 51
(56.6%) had systolic blood pressure in the range of 120-150, 35 (38.9%) had <120,
4 (4.5%) had >150. Majority of the patients 51 (56.7%) had diastolic blood pressure
in the range of 80-100, followed by 39 (43.3%) who had <80. Majority of the patients
39 (43.3%) had total cholesterol in the range of 100-150, followed by 44 (48.9%)
who were in the range of 150-200 and followed by 2 (2.2%) had >200. Majority of
the patients 49 (54.4%) had HDL in the range of 30-60, followed by 26 (28.9%) who
were in the range of 0-30, followed by 15 (16.7%) who had 60-90. Majority of the
patients 82 (91.1%) were married followed by 6 (6.7%) were single and 2 (2.2%)
were divorced. Majority of the patients 58 (64.4%) had a CD4 cell count of <=150,
followed by 13 (14.4%) were in the range of 150-300 cells, followed by 11 (12.3%)
were in the range of 300-500 cells followed by 8 (8.9%) had more than 500 cells.
Majority of the patients 83 (92.2%) were not on any hypertensive medication,
followed by 7 (7.8%) were on medication.
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Table-2 Co-Morbid Conditions Associated with Cardiovascular Risk Scores
ACC/AHA
SCORE
N=141(%)

FRAMINGHAM SMART
SCORE
SCORE
N=133(%)
N=90(%)

YES

14(9.9)

14(10.5)

13(14.4)

NO

127(90.1)

119(89.5)

77(85.6)

Cerebrovascular
Disease

YES

1(0.7)

1(0.7)

NO

140(99.3)

132(99.3)

90(100.0)

Other
Cardiovascular
Diseases

YES

4(2.8)

4(3.0)

3(3.3)

NO

137(97.2)

129(97.0)

87(96.7)

Diabetes

-

Out of 141 patients enrolled, the co-morbid conditions associated with the
cardiovascular risks were diabetes, coronary artery diseases, cerebrovascular
diseases, abdominal aortic aneurysm, peripheral artery diseases, and other
cardiovascular diseases. Out of which majority people had diabetes 14 (9.9%)
followed by other cardiovascular diseases 4 (2.8%) such as, Deep vein thrombosis
(DVT) and hypertension followed by cerebrovascular diseases 1 (0.7%).
Out of 133 patients calculated with Framingham score, the co-morbid
conditions associated with the cardiovascular risks were diabetes, coronary artery
diseases, cerebrovascular diseases, abdominal aortic aneurysm, peripheral artery
diseases, and other cardiovascular diseases. Out of which majority people had
diabetes 14 (10.5%) followed by other cardiovascular diseases 4 (3%) such as DVT
and hypertension, followed by cerebrovascular diseases 1 (0.7%).
Out of 90 patients calculated with SMART score, the co-morbid conditions
associated with the cardiovascular risks were diabetes, coronary artery diseases,
cerebrovascular diseases, abdominal aortic aneurysm, peripheral artery diseases, and
other cardiovascular diseases. Out of which majority people had diabetes 13 (14.4%)
followed by other cardiovascular diseases 3 (3.3%).
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Table-3 Opportunistic Infections
ACC/AHA
SCORE
N=141(%)

FRAMINGHAM SMART
SCORE
SCORE
N=133(%)
N=90(%)

YES

108(76.6)

102(76.7)

74(82.2)

NO

33(23.4)

31(23.3)

16(17.8)

YES

13(9.2)

11(8.3)

8(8.9)

NO

128(90.8)

122(91.7)

82(91.1)

YES

7(5.0)

6(4.5)

NO

134(95.0)

127(95.5)

90(100.0)

Pneumocystis
pneumonia

YES

1(0.7)

1(0.7)

1(1.1)

NO

140(99.3)

132(99.3)

89(98.9)

Toxoplasmosis

YES

2(1.4)

2(1.5)

2(2.2)

NO

139(98.6)

131(98.5)

88(97.8)

2(1.4)

2(1.5)

1(1.1)

139(98.6)

131(98.5)

89(98.9)

Tuberculosis

Candidiasis

Tb Meningitis

Cryptococcal Pneumonia YES
NO

-

Out of 141 patients enrolled 133 people were presented with OIs, most of the
OIs was Tuberculosis (TB) 108 (76.6%), followed by 13 (9.2%) candidiasis, 7 (5%)
Tb Meningitis, almost same frequency 2 (1.4%) for Toxoplasmosis and cryptococcal
pneumonia and Pneumocystis Pneumonia (PCP) was 1 (0.7%)
Out of 133 patients calculated with Framingham score, 124 people were
presented with opportunistic infections, among these the most common found was
Tuberculosis (TB) 102 (76.7%), 11 (8.3%) candidiasis, 6 (4.5%) for Tb Meningitis,
almost same frequency 2 (1.5%) for Toxoplasmosis and cryptococcal pneumonia
and Pneumocystis Pneumonia (PCP) was 1 (0.7%)
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Out of 90 patients calculated with SMART score 86 people were presented
with opportunistic infections, among these the most commonly found was
Tuberculosis (TB) 74 (82.2%), 8 (8.9%) candidiasis, 2 (2.2%) for Toxoplasmosis,
cryptococcal pneumonia and Pneumocystis Pneumonia (PCP) was 1 (1.1%)
Table-4: Implication of HAART Associated With Cardiovascular Risk Scores.
HAART COMBINATION

ACC/AHA
SCORE
N=141(%)
20(14.2)

FRAMINGHAM
SCORE
N=133(%)
19(14.3)

SMART
SCORE
N=90(%)
15(16.7)

47(24.1)

45(24.0)

31(23.3)

6(4.3)

6(4.5)

4(4.4)

8(5.7)

7(5.3)

2(2.2)

6(4.3)

6(4.5)

3(3.3)

7(5.0)

7(5.3)

6(6.7)

2(1.4)

2(1.5)

0(0.0)

1(0.7)

1(0.7)

0(0.0)

Atazanavir+Ritonavir (ATV+RTV)

1(0.7)

1(0.7)

0(0.0)

Tenofovir (TDF)

2(1.4)

1(0.7)

1(1.1)

Effavirenz+Emtricitabine+Tenofovir
(EFV+FTC+TDF)
Emtricitabine+Tenofovir+Effavirenz
(FTC+TDF+EFV)
Emtricitabine+Tenofovir+Effavirenz
(FTC+TDF+EFV)

24(17.0)

22(16.5)

13(14.4)

1(0.7)

1(0.7)

1(1.1)

8(5.7)

7(5.3)

6(6.7)

Emtricitabine+Tenofovir (FTC+TDF)

1(0.7)

1(0.7)

1(1.1)

Zudovidine+Lamuvidine (ZDV+3TC)

1(0.7)

1(0.7)

1(1.1)

Lamuvidine+Tenofovir+Effavirenz

2(1.4)

2(1.5)

2(2.2)

1(0.7)

1(0.7)

1(1.1)

Tenofovir
(TDF)
Tenofovir+Lamuvidine+Effavirenz
(T.TDF+3TC+EFV)
Lamuvidine+Zudovidine+Neviripine
(3TC+ZDV+NVP)
Lamivudine
(3TC)
Atazanavir+Ritonavir+Tenofovir+Emtricitabine
(ATV+RTV+TDF+FTC)
Lamuvidine+Zudovidine+Effavirenz
(3TC+ZDV+EFV)
Tenofovir+ Emtricitabine
(TDF+FTC)
Entacavir (ETV)

(3TC+TDF+EFV)
Effavirenz+Lamuvidine (EFV+3TC)
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ABACAVIR+LAMUVIDINE (ABC+3TC)

1(0.7)

1(0.7)

1(1.1)

HAART From ART Center (Combination

2(1.4)

2(1.5)

2(2.2)

Unknown)

Highest prescribed combination was found to be Tenofovir + Lamivudine +
Efavirenz (T.TDF+3TC+EFV) 34(24.1%), followed by Effavirenz + Emtricitabine
+ Tenofovir (EFV+FTC+TDF) 24 (17%), followed by Tenofovir (TDF) 20 (14.2%),
followed

by

Lamivudine

(3TC)

and

Emtricitabine+Tenofovir+Effavirenz

(FTC+TDF+EFV) with 8 (5.7%).
Table-5: Duration Of HAART Associated With Cardiovascular Risk Scores :
ACC/AHA
SCORE

FRAMINGHAM SMART
SCORE
SCORE

N=141(%)

N=133(%)

Newly Diagnosed

4(2.8)

4(3.0)

One Year

45(31.9)

39(29.3)

27(30)

Two Years

44(31.2)

42(31.6)

25(27.8)

Three Years

12(8.5)

12(9.0)

10(11.1)

Four Years

8(5.7)

8(6.0)

5(5.6)

Five Years

5(3.5)

5(3.8)

5(5.6)

Six Years

5(3.5)

5(3.8)

4(4.4)

Seven Years

3(2.1)

3(2.3)

2(2.2)

Eight Years

4(2.8)

4(3.0)

3(3.3)

Nine Years

2(1.4)

2(1.5)

1(1.1)

Ten Years

3(2.1)

3(2.3)

2(2.2)

Twelve Years

3(2.1)

3(2.3)

3(3.3)

DURATION

N=90(%)
---
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Sixteen Years

1(0.7)

1(0.7)

1(1.1)

Seventeen Years

1(0.7)

1(0.7)

1(1.1)

Twentytwo Years

1(0.7)

1(0.7)

1(1.1)

Duration Of HAART Associated With Cardiovascular Risk Scores
45
45

39

40

44
42

35
27

No. of Patients

30

25

25
20
1212
10

15
10
5

44

88

5

0

555

554

332

443

221

332

333

111

111

111

0

ACC/AHA SCORE

FRAMINGHAM SCORE

SMART SCORE

Out of 141 patients, according to ACC/AHA Score highest duration of
HAART regimen was observed in one year 45 (31.9%), followed by two years 44
(31.2%), followed by three years 12 (8.5%), followed by four years 8 (5.7%),
followed by five and six years with 5 (3.5%), followed by eight years and newly
diagnosed with 4 (2.8%), followed by seven years, ten years and twelve years with
3 (2.1%), followed by nine years with 2 (1.4%), followed by sixteen years, seventeen
years and twenty two years with 1 (0.7%).
Out of 133 patients, according to Framingham Score highest duration of
HAART regimen was observed in two years 42 (31.6%), followed by one year 39
(29.3%), followed by three years 12 (9%), followed by four years 8 (6%), followed
by five and six years with 5 (3.8%), followed by eight years and newly diagnosed
with 4 (3%), followed by seven years, ten years and twelve years with 3 (2.3%),
followed by nine years with 2 (1.5%), followed by sixteen years, seventeen years
and twenty two years with 1 (0.7%).
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Out of 90 patients, according to SMART Score highest duration of HAART
regimen was observed in one year 27 (30%), followed by two years 25 (27.8%),
followed by three years 10 (11.1%), followed by four years and five years with 5
(5.6%), followed by six years with 4 (4.4%), followed by eight years and twelve
years with 3 (3.3%), followed by seven years and ten years with 2 (2.2%), followed
by sixteen years, seventeen years, nine years and twenty two years with 1 (1.1%).

Table-6 Duration of Co-Morbid Illness Associated With Cardiovascular Risk Scores

Duration Of
Comorbid Illness

ACC/AHA
SCORE
N=141(%)

FRAMINGHAM SMART
SCORE
SCORE
N=133(%)
N=90(%)

No comorbid
illness

128(90.8)

120(90.2)

80(88.9)

One Year

6(4.3)

6(4.5)

5(5.5)

Two Years

1(0.7)

1(0.7)

1(1.1)

Three Years

2(1.4)

2(1.5)

Four Years

1(0.7)

1(0.7)

1(1.1)

Five Years

1(0.7)

1(0.7)

1(1.1)

Six Years

1(0.7)

1(0.7)

1(1.1)

Eight Years

1(0.7)

1(0.7)

1(1.1)

--
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Duration of Co-Morbid Illness Associated With Cardiovascular Risk
Scores
140
128
120
120

No. of Patients

100
80
80
60
40
20
6 6 5

1 1 1

2 2 0

1 1 1

1 1 1

1 1 1

1 1 1

Two Years

Three Years

Four Years

Five Years

Six Years

Eight Years

0
None

One Year

ACC/AHA SCORE

FRAMINGHAM SCORE

SMART SCORE

Out of 141 patients enrolled, according to ACC/AHA Score, the highest
duration of co-morbid illness was one year 6 (4.3%), followed by three years 2
(1.4%), followed by two, four, five, six and eight years with 1 (0.7%).
Out of 133 patients enrolled, according to Framingham Score, the highest
duration of co-morbid illness was one year 6 (4.5%), followed by three years 2
(1.5%), followed by two, four, five, six and eight years with 1 (0.7%).
Out of 90 patients enrolled, according to SMART Score, the highest duration
of co-morbid illness was one year 5 (5.5%), followed by two, four, five, six and eight
years with 1 (1.1%).
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Table-7 Assessment Of Cardiovascular Risk Scores
ACC/AHA FRAMINGHAM SMART
SCORE
SCORE
SOCRE
(N=141)

(N=133)

(N=90)

Low Risk

108(75.9)

92(65.2)

47(33.3)

Moderate Risk

29(20.6)

24(17.0)

42(29.8)

Severe Risk

4(2.8)

17(12.1)

1(0.7)

Assessment Of Cardiovascular Risk Scores
120

No. of Patients

100

108
92

80
60
47
40

42
29

24
17

20
4

1

0
LOW RISK
ACC/AHA SCORE

MODERATE RISK
FRAMINGHAM SCORE

SEVERE RISK
SMART SOCRE

Out of 141 patients enrolled, according to ACC/AHA Score 108 (75.9%) were
scored low risk, 29 (20.6%) were scored moderate risk and 4 (2.8%) were scored
severe risk.
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Out of 133 patients enrolled, according to Framingham Score 92 (65.2%) were
scored low risk, 24 (17%) were scored moderate risk and 17 (12.1%) were scored
severe risk.
Out of 90 patients enrolled, according to SMART Score 47 (33.3%) were
scored low risk, 42 (29.8%) were scored moderate risk and 1 (0.7%) were scored
severe risk.

Table-8 Comparison of AHA Score & Framingham Score
Framingham
Score

AHA Score

Total
(N=90)

Low
Risk

Moderate Severe
Risk
Risk

Low Risk

47

21

0

68

Moderate Risk

2

3

0

5

Severe Risk

0

13

4

17

Kappa
value

0.282

For comparison of all the three scores the N=90 is taken as common.
Out of 90 patients assessed with both Framingham and AHA score, 47 patients
were categorized as low risk by both the scores, 21 patients were categorized as low
risk by Framingham score whereas they were categorized as moderate risk by AHA
score. 2 patients were categorized as moderate risk by Framingham score whereas
they were categorized as low risk by AHA score, 3 patients were categorized as
moderate by both the scores. 13 patients were categorized as a severe risk by
Framingham score whereas they were categorized as moderate by AHA score & 4
patients were categorized as a severe risk by both the scores.
The Cohen’s kappa coefficient value for the degree of agreement between the
scores was found to be 0.282 (Fair agreement)
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Table-9 Comparison of SMART Score & AHA Score
SMART Score

AHA Score

Total

Low
Risk

Moderate
Risk

Severe
Risk

Low Risk

40

7

0

47

Moderate Risk

9

30

3

42

Severe Risk

0

0

1

1

Kappa
value

0.597

Out of 90 patients assessed with both SMART and AHA scores, 40 patients
were categorized as low risk, 7 patients were categorized as low risk by SMART
score whereas they were categorized as a moderate risk by AHA score. 9 patients
were categorized as a moderate risk by SMART score whereas they were categorized
as low risk by AHA score, 30 patients were categorized as moderate by both the
scores. 3 patients were categorized as a moderate risk by SMART score whereas
they were categorized as a severe risk by AHA score & 4 patients were categorized
as a severe risk by both the scores.
The Cohen’s kappa coefficient value for the degree of agreement between the
scores was found to be 0.597 (Moderate agreement)
Table-10 Comparison of Framingham Score & SMART Score
Framingham
Score

SMART Score

Total

Low
Risk

Moderate
Risk

Severe
Risk

Low Risk

46

22

0

68

Moderate Risk

1

4

0

5

Severe Risk

0

16

1

17

Kappa
value

0.250
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Out of 90 patients assessed with both Framingham and SMART score, 46
patients were categorized as low risk by both, 22 patients were categorized as low
risk by Framingham score whereas they were categorized as a moderate risk by
SMART score. 1 patient was categorized as a moderate risk by Framingham score
whereas categorized as low risk by SMART score, 4 patients were categorized as
moderate by both the scores. 16 patients were categorized as a severe risk by
Framingham score whereas they were categorized as moderate by SMART score &
1 patient was categorized as a severe risk by both the scores.
The Cohen’s kappa coefficient value for the degree of agreement between the
scores was found to be 0.250 (Fair agreement)
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DISCUSSION:
This study included the assessment of CVD risk in PLW-HIV using three
different cv risk scores, such as ACC/AHA score, Framingham score and SMART
score. The minimum age for calculating the cv risk varied for each score, the
minimum age for SMART score was 40 yrs, Framingham was 30 yrs and ACC/AHA
was 18 yrs.
Achhra et al found that the risk of all CVD and many cancers increased at low
BMI ( <18 ) and high BMI (>30) respectively(6). Our study showed that most of the
people have BMI <19.9 and out of which 6 had severe risk of CVD according to
Framingham score and 5 people had severe risk in <19.9 range according to
ACC/AHA score and 4 people had severe risk in <19.9 range according to SMART
score.
Alcohol drinking did not show a significant effect on the variation in the
scores, all the three scores depicted almost similar results for the cv risk in people
drinking alcohol, although according to Freiberg et al hazardous drinking and
alcohol abuse showed a significant increase in cv risk in PLW-HIV when compared
to non-drinkers(7).
According to Marcus et al Abacavir combination of HAART showed 2-fold
greater risk of cvd than compared to other combinations of HAART. In this study
only one patient was prescribed with abacavir based regimen(8).
Cohen’s Kappa coefficient is used to find out the degree of agreement between
two variables. When the results of the Framingham score was compared with that of
the AHA score the kappa coefficient value obtained was 0.282 which shows a fair
agreement (0.21 – 0.40)(9) between these two scores. In a similar way, the results of
SMART score was compared with that of AHA score, the kappa coefficient value
was 0.597 which shows a moderate agreement (0.41 – 0.60) between the scores. And
when the results of the Framingham score were compared with SMART score the
kappa coefficient value was 0.250 which shows a fair agreement (0.21 – 0.40)
between the scores.
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6. LIMITATIONS:
 The minimum age for calculating the cardiovascular risk scores was different
for each score.
 It is a retrospective study comparing three different CV risk scores. Certainly,
the best way to compare those scores should be a prospective study observing
how these scores work as an HIV cohort grows older.
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7. CONCLUSION:
This study was conducted to compare the various standard CV risk scores
like ACC/AHA score, Framingham score and SMART score in PLW-HIV. All
the demographic details of the patients, co-morbid conditions, duration of comorbid conditions, HAART combination prescribed for each patient were
documented and compared with respect to each score.
The three cardiovascular risk scores when compared with each other for
their degree of agreement showed fair agreement between Framingham and
AHA score and Framingham and SMART score and the comparison between
AHA and SMART score showed moderate agreement.
ACC/AHA score is the most commonly used score for cv risk scoring
India, and when it was compared with Framingham and SMART score showed
fair to moderate agreement these scores can also be used in addition to AHA
score for calculating cv risk scores in India.
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INDIVIDUAL CASE REPORT FORM

1.Hospital No. :

2. IP No. :

2.Age :
3.Sex :

Male 

4.Height :

Female 

Others 

5.Weight :

7.B.P :

6.BMI :

8.Total cholesterol :

9.HDL cholesterol :
Yes 

10.B.P Medication :

No 

11.If yes with dose,

12.Use of Alcohol : Never 

Social 

Habitual 

13.Smoking : Past smoker 

Never 

Current Smoker 

14.Diet : Vegetarian 

Reformed 

Mixed Diet 

15.Duration of HAART :
16.Marital Status : Married 
Employed 

17.Employment :
18.CD4 Count :

Unmarried 

a) Initial :

Divorced 

Widower  Separated 

Unemployed 
b) Final :

c) Follow-up 

19.Medical History :
Diabetes 

Coronary Artery Disease 

Cerebrovascular Disease 

Abdominal Aortic Aneurysm 

Peripheral Artery Disease 

Other Cardiovascular Diseases 
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20.Time since first diagnosis of Cardiovascular Disease :

21.Opportunistic Infections : Present 

Absent 

TB  Candidiasis  CMV  TB Meningitis  PCP  HZ  PGL  Scabies 
Toxoplasmosis  Cryp. Pneumonia  Cryp. Neoformans  Cryp. Sporidio 

22.HAART Combination :
T. TENVIR
T. TRIODAY
T. DUOVIR-N
T. LAMIVIR
T. QVIR KIT
T. DUOVIR-EKIT
T. TENVIR-EM
T. LAMIVIR E
T. ENTALIV
T. SYNTHIVAN
T. REVIRO
T. TENOLAM E
T. VIRADAY

TDF
TDF+3TC+EFV
3TC+ZDV+NVP
3TC
ATV+RTV+TDF+FTC
3TC+ZDV+EFV
TDF+FTC
D4T+3TC
ETV
ATV+RTV
TDF
TDF+3TC+EFV
EFV+FTC+TDF

23.Framingham Risk Score :
Low risk 

Moderate risk 

Severe risk 

24.ACC/AHA Risk Score :
Low risk 

Moderate risk 

Severe risk 

Moderate risk 

Severe risk 

25.SMART Score :
Low risk 

26.Outcomes based on all the scores :
Low risk 

High risk 
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ACC/AHA SCORE:
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FRAMINGHAM RISK SCORE:
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